CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib, to prevent acute graft-versus-host disease (GVHD).
Pacritinib showed an encouraging safety profile and exhibited preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic cell transplantation.
The Phase 2 portion of the trial is designed to evaluate the therapeutic effect of pacritinib in combination with sirolimus and low-dose tacrolimus for GVHD prevention.
The Phase 1 portion of the trial evaluated the safety of pacritinib when administered with sirolimus, plus low-dose tacrolimus after allogeneic hematopoietic cell transplantation.
A 3+3 dose escalation design identified Pacritinib 100 mg twice a day as the minimum biologically active and well-tolerated dose for further study.
The new manuscript reports that dual JAK2/mTOR inhibition suppresses pathogenic Th1 and Th17 cells, enhances the potency of immunosuppressive regulatory T cells (Tregs) and maintains natural killer cells and CD8+ cytotoxic T lymphocytes required for graft-versus-leukemia.
Notably, PAC/SIR/TAC was observed to preserve donor cytomegalovirus (CMV) immunity, permit timely engraftment, and avoid cytopenias observed with nonselective JAK inhibitors.
Pacritinib is an oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development and inflammatory cytokine expression and immune responses.
Price Action: CTIC shares trading 2.03% higher at $3.27 in market hours on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.